On Thursday, Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares inclined 8.07% to $3.48.
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, recently declared new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2125 alone and in combination with ipilimumab demonstrated potent and systemic anti-tumor activity in preclinical cancer models. IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Additionally, Idera presented preclinical data which demonstrated that IMO-2125 induces a systemic antitumor immune response with the potential to sensitize the tumor microenvironment for combination with various checkpoint inhibitors. These data are being presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference in New York City, starting recently.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
Aecom(NYSE:ACM)’s shares dropped -0.65% to $27.54.
AECOM (ACM), a premier, fully integrated global infrastructure firm, recently declared the appointment of W. Troy Rudd as executive vice president and chief financial officer, effective Oct. 5.
Rudd, a senior vice president conpresently serving as treasurer; chief operating officer, Design Consulting Services (DCS) Americas; and chief financial officer, DCS Global, assumes the CFO role held by AECOM President Stephen M. Kadenacy, who has served as CFO since 2011. As president, Kadenacy will take on a broader operational responsibility across the organization, while ongoing to be responsible for a wide range of critical corporate functions.
AECOM, together with its auxiliaries, provides professional technical and administration support services for public and private clients worldwide. The company operates through two segments, Professional Technical Services (PTS) and Administration Support Services (MSS).
At the end of Thursday’s trade, IMAX Corporation (USA) (NYSE:IMAX)‘s shares surged 1.30% to $34.29.
IMAX Corporation (IMAX) declared that IMAX China Holding, Inc., a Cayman Islands company and a partner of IMAX, filed a post-hearing information pack (“PHIP”) with the Hong Kong Stock Exchange in connection with its initial public offering. Comprised Of in the PHIP is a disclosure document with updated financials as of June 30, 2015.
The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws, and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
IMAX Corporation, together with its auxiliaries, operates as an entertainment technology company specializing in motion picture technologies and presentations worldwide. The company operates in seven segments: IMAX Systems, Theater System Maintenance, Joint Revenue Sharing Arrangements, Film Production and IMAX Digital Re-Mastering (DMR), Film Distribution, Film Post-Production, and Other. The IMAX Systems segment designs, manufactures, sells, or leases IMAX theater projection system equipment. The Theater System Maintenance segment maintains IMAX theater projection system equipment in the IMAX theater network.
Varian Medical Systems, Inc . (NYSE:VAR), ended its Thursday’s trading session with -0.11% loss, and closed at $78.64.
Varian Medical Systems (VAR) is announcing several events for investors, counting its ASTRO investor meeting in San Antonio, TX, its fourth quarter and fiscal year 2015 earnings report and conference call, and a fiscal 2015 year-end & fiscal 2016 outlook meeting in New York.
ASTRO IR Day
Varian administration will host its ASTRO investor meeting on Tuesday, October 20 at the annual meeting of the American Society for Radiation Oncology. The investor meeting in the Texas Ballroom at the Grand Hyatt San Antonio, 600 E. Market St., will start with breakfast at 7:00 a.m. with the webcast presentations starting at 7:30 CT followed by a tour of the Varian booth at 9:00 a.m. The webcast can be accessed at http://investors.varian.com/events-webcasts.
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions in the United States. The company operates in two segments, Oncology Systems and Imaging Components. The Oncology Systems segment provides hardware and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery, and brachytherapy.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
